Skip to search formSkip to main contentSkip to account menu

IPH2201

Known as: IPH-2201 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monalizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.
3540Background: Monalizumab (IPH2201) is a humanized IgG4 antibody targeting CD94/NKG2a to suppress inhibitory signaling by… 
2018
2018
Abstract 1690: NKG2A immune checkpoint blockade potentiates cetuximab induced ADCC in head and neck cancer preclinical model
Monalizumab (IPH2201) is a first-in-class humanized IgG4 targeting NKG2A (Natural Killer Group 2A), which is expressed as a… 
2017
2017
Abstract 5666: Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the…
Background: Monalizumab (IPH2201) is a first-in-class immune checkpoint inhibitor targeting CD94-NKG2A receptors expressed on… 
2016
2016
Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221
2016
2016
Abstract 2342: NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model
Monalizumab (IPH2201) is a novel, first-in-class humanized IgG4 targeting the immune checkpoint receptor NKG2A (Natural Killer… 
2015
2015
Immuno-oncology moves beyond PD-1
673 Ugur Sahin, CEO of Mainz, Germany–based BioNTech. “We believe there’s ample evidence macrophages can create an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)